Why CGTX Stock dropped -5.57% Today — RQD Quant Desk Flash

Per the Roarable RQD rating, CGTX scores 43 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The fundamental cash engine pillar scores 6 out of 20, reflecting ROIC of -35% and an FCF yield of 0%, which signals that the business is not currently generating returns on invested capital or free cash. The whale and 13F flow pillar scores 12 out of 20, labeled as institutional accumulation and options positioning, the strongest of the five pillars but still below midpoint. The insider conviction pillar scores 5 out of 20, reflecting SEC Form 4 and Congressional PTR cluster flow. The macro regime fit pillar scores 10 out of 20, with a beta of 1.0 and sector sensitivity noted. The forensic balance sheet pillar scores 10 out of 20, referencing an Altman Z-Score of 2.5, a Piotroski F-Score of 2 out of 9, and a Debt/Equity ratio of 0.5. For a prospective investor evaluating the stock today, the pattern is that the rating's weakest inputs are the cash-generation and insider-conviction pillars, meaning the thesis rests more on sentiment, catalysts, and balance-sheet runway than on current operating earnings. Upside drivers would need to come from the regulatory and clinical catalysts described in the news wire, while the valuation tradeoff is that a $70.3M market capitalization is being assigned against operating losses of $-47.8M in FY 2025.

Per the SEC financials, the company reported no revenue and operating losses in each period, with gross, operating, and net margins all shown as 0% in the market data. ROIC is -35% per the market data. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, both per the Roarable RQD rating's forensic balance sheet pillar. The Debt/Equity ratio is 0.5 per the same source, while the debt line in the financials is reported as N/A. Cash increased from $25.0M in FY 2024 to $36.8M in FY 2025 per the SEC financials.

Per the recent news and catalysts feed, the most prominent catalyst is the company's alignment with the FDA on a planned Phase 3 trial of zervimesine (CT1812) in dementia with Lewy bodies, reported across multiple outlets. A second headline notes an FDA meeting ahead of which H.C. Wainwright reiterated its rating on the stock. Another item references a drug patent running to 2045 with FDA approval potentially allowing up to five more years of exclusivity. A GlobeNewswire item titled around an "Issuance of Composition" is listed without further detail in the source. Every news item is tagged with a YELLOW light and MARKET WIRE impact label, and the source does not provide a risk-watch list or additional proprietary signals beyond these headlines. The Butterfly supply-chain graph lists no supply chain and no proprietary signals.

• What is the company's revenue model and product pipeline, given reported revenue of $0.0M in each period?
• What is the outcome and timing of the FDA meeting referenced in the news wire, and how does it affect the planned Phase 3 trial?
• What is the debt position, given the financials report debt as N/A while the rating cites a Debt/Equity ratio of 0.5?
• What are the specific insider Form 4 and Congressional PTR transactions behind the insider conviction score of 5 out of 20?
• How long does the reported cash balance of $36.8M fund operating losses at the FY 2025 level of $-47.8M?